Abstract:Purpose of review: Opioid receptors are widely expressed in the human brain. A number of features commonly associated with drug use disorder, such as difficulties in emotional learning, emotion regulation and anhedonia, have been linked to endogenous opioid signalling. Whereas chronic substance use and misuse are thought to alter the function of the mu-opioid system, the specific mechanisms are not well understood. We argue that understanding exogenous and endogenous opioid effects in the healthy human brain is an essential foundation for bridging preclinical and clinical findings related to opioid misuse. Here, we will examine psychopharmacological evidence to outline the role of the mu-opioid receptor (MOR) system in the processing of threat and reward, and discuss how disruption of these processes by chronic opioid use might alter emotional learning and reward responsiveness. Recent findings: In healthy people, studies using opioid antagonist drugs indicate that the brain's endogenous opioids downregulate fear reactivity and upregulate learning from safety. At the same time, endogenous opioids increase the liking of and motivation to engage with high reward value cues. Studies of acute opioid agonist effects indicate that with non-sedative doses, drugs such as morphine and buprenorphine can mimic endogenous opioid effects on liking and wanting. Disruption of endogenous opioid signalling due to prolonged opioid exposure is associated with some degree of anhedonia to non-drug rewards; however, new results leave open the possibility that this is not directly opioid-mediated. Summary: The available human psychopharmacological evidence indicates that the healthy mu-opioid system contributes to the regulation of reward and threat processing. Overall, endogenous opioids can subtly increase liking and wanting responses to a wide variety of rewards, from sweet tastes to feelings of being connected to close others. For threat-related processing, human evidence suggests that endogenous opioids inhibit fear conditioning and reduce the sensitivity to aversive stimuli, although inconsistencies remain. The size of effects reported in healthy humans are however modest, clearly indicating that MORs play out their role in close concert with other neurotransmitter systems. Relevant candidate systems for future research include dopamine, serotonin and endocannabinoid signalling. Nevertheless, it is possible that endogenous opioid fine-tuning of reward and threat processing, when unbalanced by e.g. opioid misuse, could over time develop into symptoms associated with opioid use disorder, such as anhedonia and depression/anxiety.

Endogenous opioids regulate moment-to-moment neuronal communication and excitability

Correction: Divergent Modulation of Pain and Anxiety by GABAergic Neurons in the Ventrolateral Periaqueductal Gray and Dorsal Raphe.

Complex opioid driven modulation of glutamatergic and cholinergic neurotransmission in a GABAergic brain nucleus associated with emotion, reward and addiction.

Synaptic properties and postsynaptic opioid effects in rat central amygdala neurons.

Polymodal Activation of the Endocannabinoid System in the Extended Amygdala.

Neuromodulation of inhibitory synaptic transmission in the basolateral amygdala during fear and anxiety

Mu and Delta Opioid Receptors Modulate Inhibition within the Prefrontal Cortex through Dissociable Cellular and Molecular Mechanisms

The Role of Mu-Opioids for Reward and Threat Processing in Humans: Bridging the Gap from Preclinical to Clinical Opioid Drug Studies

Opioid Signal Transduction Regulates The Dendritic Morphology Of Somatostatin And Parvalbumin Interneurons In The Medial Prefrontal Cortex

Presynaptic inhibition of excitatory synaptic transmission from the calcitonin gene-related peptide-containing parabrachial neurons to the central amygdala in mice – unexpected influence of systemic inflammation thereon

Endogenous opioid dynamics in the dorsal striatum sculpt neural activity to control goal-directed action

Unlocking opioid neuropeptide dynamics with genetically encoded biosensors

Switching of Delta Opioid Receptor Subtypes in Central Amygdala Microcircuits is Associated with Anxiety States in Pain

Oxytocin Differentially Modulates Amygdala Responses During Top-Down and Bottom-Up Aversive Anticipation

Divergent opioid-mediated suppression of inhibition between hippocampus and neocortex across species and development

Opioid Withdrawal Abruptly Disrupts Amygdala Circuit Function by Reducing Peptide Actions

Opioid system and human emotions

μ-Opioid receptor antagonism facilitates the anxiolytic-like effect of oxytocin in mice

μ-opioid-mediated inhibition of glutamate synaptic transmission in rat central amygdala neurons

354 Possible Conduction Block by Mu Opioid in Primary Afferent Fibers in the Spinal Dorsal Horn

Opioids and anxiety